Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07421518 · ClinicalTrials.gov registry record · Phase 2
Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors
A Phase 2 study, sponsored by AdventHealth Translational Research Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT07421518 is a Phase 2 study that has not yet begun recruiting, run by AdventHealth Translational Research Institute. The registered enrollment target is 75 participants.
The verdict
NCT07421518, a Phase 2 study, has not yet begun recruiting, sponsored by AdventHealth Translational Research Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
The purpose of this research is to see how well a special education plan using continuous ketone monitoring (DGK) works to lower the risk of a condition called diabetic ketoacidosis (DKA) in people with type 1 diabetes (T1D) taking SGLT2 inhibitors (a type of medication commonly used to treat type 2 diabetes). This special education plan is compared to a general education plan and considers the higher risk of DKA when using medicines like SGLT2 inhibitors.
Interventions
- DRUG SGLT-2 inhibitor (Sotagliflozin)
- OTHER Insulin withdrawal test (IWT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-06 |
| Est. Completion | 2030-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07421518
The ClinicalTrials.gov registry entry for NCT07421518 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth Translational Research Institute, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SGLT-2 inhibitor (Sotagliflozin) is the first listed.
NCT07421518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07421518 about?
NCT07421518 is a clinical study titled "Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors". The purpose of this research is to see how well a special education plan using continuous ketone monitoring (DGK) works to lower the risk of a condition called diabetic ketoacidosis (DKA) in people with type 1 diabetes (T1D) taking SGLT2 inhibitors (a type of medication commonly used to treat type 2...
What is the current status of trial NCT07421518?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-06. Estimated completion is 2030-04.
What interventions are being tested in trial NCT07421518?
The interventions under investigation include: SGLT-2 inhibitor (Sotagliflozin) (DRUG), Insulin withdrawal test (IWT) (OTHER).
Who is sponsoring clinical trial NCT07421518?
This trial is sponsored by AdventHealth Translational Research Institute, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.